Oncogene withdrawal engages the immune system to induce sustained cancer regression

Journal for ImmunoTherapy of Cancer

Dean W Felsher¹  Alice C Fan¹  Yulin Li¹  Stephanie C Casey¹ 

[1] Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, 269 Campus Drive, CCSR 1105, Stanford 94305-5151, CA, USA

关键词: Tumor immunology;    Tumor microenvironment;    MYC;    Oncogene addiction;   

Others  :  1139877
DOI  :  10.1186/2051-1426-2-24

 received in 2014-03-11, accepted in 2014-06-06,  发布年份 2014

【 摘 要 】

The targeted inactivation of a single oncogene can induce dramatic tumor regression, suggesting that cancers are “oncogene addicted.” Tumor regression following oncogene inactivation has been thought to be a consequence of restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and cellular senescence. However, recent observations illustrate that oncogene addiction is highly dependent upon the host immune cells. In particular, CD4⁺ helper T cells were shown to be essential to the mechanism by which MYC or BCR-ABL inactivation elicits “oncogene withdrawal.” Hence, immune mediators contribute in multiple ways to the pathogenesis, prevention, and treatment of cancer, including mechanisms of tumor initiation, progression, and surveillance, but also oncogene inactivation-mediated tumor regression. Data from both the bench and the bedside illustrates that the inactivation of a driver oncogene can induce activation of the immune system that appears to be essential for sustained tumor regression.

【 授权许可】

   
2014 Casey et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Felsher DW, Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999, 4:199-207.
• [2]Felsher DW: Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003, 3:375-380.
• [3]Weinstein IB: Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002, 297:63-64.
• [4]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [5]Felsher DW: Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 2008, 68:3081-3086. discussion 3086
• [6]Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698.
• [7]Sharma SV, Settleman J: Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007, 21:3214-3231.
• [8]Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 2010, 107:18545-18550.
• [9]Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, et al.: The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
• [10]Restifo NP: Can antitumor immunity help to explain "oncogene addiction"? Cancer Cell 2010, 18:403-405.
• [11]Furth PA: Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations. Ann N Y Acad Sci 2012, 1271:1-9.
• [12]Ding ZC, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH, Zhou G: Polyfunctional CD4(+) T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 2012, 120:2229-2239.
• [13]Ding ZC, Zhou G: Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012, 2012:890178.
• [14]Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T, Daniel P, Yu H, Charo J, Blankenstein T: Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 2011, 20:755-767.
• [15]Shortt J, Johnstone RW: Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol 2012, 1:4(12).
• [16]Baker SJ, Reddy EP: Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010, 77:573-586.
• [17]Houshmand P, Zlotnik A: Targeting tumor cells. Curr Opin Cell Biol 2003, 15:640-644.
• [18]Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11:873-886.
• [19]O'Bryant CL, Wenger SD, Kim M, Thompson LA: Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 2013, 47:189-197.
• [20]Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C: ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013, 8:55-67.
• [21]Blay JY, Le Cesne A, Alberti L, Ray-Coquart I: Targeted cancer therapies. Bull Cancer 2005, 92:E13-18.
• [22]Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D: Added value of molecular targeted agents in oncology. Ann Oncol 2011, 22:1703-1716.
• [23]Nagai S, Takahashi T, Kurokawa M: The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Curr Stem Cell Res Ther 2010, 5:372-378.
• [24]Casey SC, Bellovin DI, Felsher DW: Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol 2013, 25:246-258.
• [25]Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013, 137:828-860.
• [26]Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J: Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012, 30:4161-4167.
• [27]Cheok CF, Verma CS, Baselga J, Lane DP: Translating p53 into the clinic. Nat Rev Clin Oncol 2011, 8:25-37.
• [28]Essmann F, Schulze-Osthoff K: Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 2012, 165:328-344.
• [29]Fruman DA, Rommel C: PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011, 1:562-572.
• [30]Roschewski M, Farooqui M, Aue G, Wilhelm F, Wiestner A: Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia 2013, 27:1920-1923.
• [31]Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A: A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012, 18:4173-4182.
• [32]Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
• [33]Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM: BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
• [34]Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
• [35]Huettner CS, Zhang P, Van Etten RA, Tenen DG: Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000, 24:57-60.
• [36]Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA: Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
• [37]Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002, 297:102-104.
• [38]Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
• [39]Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006, 66:999-1006.
• [40]Boxer RB, Jang JW, Sintasath L, Chodosh LA: Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6:577-586.
• [41]Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegue E, Tang F, Folkman J, Felsher DW: Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 2006, 103:16266-16271.
• [42]Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN, Cleveland JL: c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002, 16:2530-2543.
• [43]Brandvold KA, Neiman P, Ruddell A: Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene 2000, 19:2780-2785.
• [44]Janz A, Sevignani C, Kenyon K, Ngo CV, Thomas-Tikhonenko A: Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 2000, 28:2268-2275.
• [45]Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW: CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
• [46]Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-147.
• [47]Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
• [48]Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
• [49]Gasser S, Raulet D: The DNA damage response, immunity and cancer. Semin Cancer Biol 2006, 16:344-347.
• [50]Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA: Elevated risk of lung cancer among people with AIDS. AIDS 2007, 21:207-213.
• [51]Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA: Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003, 32:527-533.
• [52]Dugue PA, Rebolj M, Garred P, Lynge E: Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther 2013, 13:29-42.
• [53]Kubica AW, Brewer JD: Melanoma in immunosuppressed patients. Mayo Clin Proc 2012, 87:991-1003.
• [54]Hoover RN: Lymphoma risks in populations with altered immunity--a search for mechanism. Cancer Res 1992, 52:5477s-5478s.
• [55]Boshoff C, Weiss R: AIDS-related malignancies. Nat Rev Cancer 2002, 2:373-382.
• [56]Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009, 69:5383-5391.
• [57]Al-Tameemi M, Chaplain M, d'Onofrio A: Evasion of tumours from the control of the immune system: consequences of brief encounters. Biol Direct 2012, 7:31.
• [58]Ribas A: Immunoediting the cancer genome–a new approach for personalized cancer therapy? Pigment Cell Melanoma Res 2012, 25:297-298.
• [59]Peggs KS, Quezada SA, Allison JP: Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224:141-165.
• [60]Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
• [61]Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Metivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G: Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014, 21(1):79-91.
• [62]Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L: Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013, 2:e23510.
• [63]Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
• [64]Pegram MD, Konecny G, Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000, 103:57-75.
• [65]Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
• [66]Shiao SL, Coussens LM: The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010, 15:411-421.
• [67]Pardoll DM: Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012, 13:1129-1132.
• [68]Acharya UH, Jeter JM: Use of ipilimumab in the treatment of melanoma. Clin Pharmacol 2013, 5:21-27.
• [69]Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH: Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013, 2:e25961.
• [70]Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13:84-88.
• [71]Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J: Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
• [72]Beatty G, Paterson Y: IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001, 166:2276-2282.
• [73]Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS: Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
• [74]Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Forster I, Huss R, Weber WA, Kneilling M, Rocken M: TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008, 13:507-518.
• [75]Lawler PR, Lawler J: Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012, 2:a006627.
• [76]Li SS, Liu Z, Uzunel M, Sundqvist KG: Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood 2006, 108:3112-3120.
• [77]Baek KH, Bhang D, Zaslavsky A, Wang LC, Vachani A, Kim CF, Albelda SM, Evan GI, Ryeom S: Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest 2013, 123:4375-4389.
• [78]Sosale N, Discher DE: Marker-of-self becomes marker-of-senescence. Blood 2012, 119:5343-5344.
• [79]Whitfield JR, Soucek L: Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci 2012, 69:931-934.
• [80]Galluzzi L, Vitale I, Kroemer G: Past, present, and future of molecular and cellular oncology. Front Oncol 2011, 1:1.
• [81]Somasundaram R, Villanueva J, Herlyn M: Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 2012, 65:335-359.
• [82]Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, Brown MP, Khanna KK: Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 2011, 32:650-658.
• [83]Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI: Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007, 13:1211-1218.
• [84]Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, Stein H, Dorken B, Jenuweins T, Schmitt CA: Tumor Stroma-Derived TGF-beta Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence. Cancer Cell 2010, 17:262-272.
• [85]Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA: The immune system–is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008, 20:101-112.
• [86]Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L: Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011, 17:351-358.
• [87]Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L: Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010, 22:113-124.
• [88]Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
• [89]Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L: Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009, 69:3563-3569.
• [90]Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
• [91]Wilmott JS, Scolyer RA, Long GV, Hersey P: Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012, 1:997-999.
• [92]Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen J, Li HS, Watowich S, Yang Y, Frederick DT, Cooper ZA, Mbofung R, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizee G, Hwu P: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Anti-tumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 2013, 19(2):393-403.
• [93]Sumimoto H, Imabayashi F, Iwata T, Kawakami Y: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203:1651-1656.
• [94]Bajor DL, Vonderheide RH: Rehabilitation for oncogene addiction: role of immunity in cellular sobriety. Clin Cancer Res 2012, 18:1192-1194.
• [95]Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013, 123:1371-1381.
• [96]Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen AW: Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? Curr Oncol Rep 2012, 14:230-239.
• [97]Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
• [98]Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, Fusi A, Schmittel A, Miller K, Thiel E, Keilholz U: Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer 2011, 47:690-696.
• [99]Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P: Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003, 3:2.
• [100]Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC, Hung CF: Immune mechanism of the antitumor effects generated by bortezomib. J Immunol 2012, 189:3209-3220.
• [101]Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG: Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010, 46:2010-2019.
• [102]Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd: IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol 2011, 186:3401-3409.
• [103]Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066-1075.
• [104]Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
• [105]Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi MR: Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One 2011, 6:e18925.
• [106]Krusch M, Salih HR: Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr Med Chem 2011, 18:5174-5184.
• [107]Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo T: Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 2012, 157:254-256.
• [108]Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S: Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010, 116:772-782.
• [109]Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Dohner H, Bunjes D, Schmitt M: Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 2007, 31:1133-1139.
• [110]Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010, 33:1-7.
• [111]Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM: Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 2011, 103:1222-1226.
• [112]Vanneman M, Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
• [113]Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
• [114]GlaxoSmithKline: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01767454 NLM Identifier: NCT01767454 webcite
• [115]National Cancer Institute: Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01940809 NLM Identifier: NCT01940809 webcite
• [116]Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, Gandara DR, Chen A, Kirkwood JM: Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res 2011, 17:6574-6581.
• [117]Azijli K, Stelloo E, Peters GJ, AJ VDE: New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 2014, 34:1493-1505.
• [118]National Cancer Institute: Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma. ClinicalTrials.gov Identifier: NCT01896999. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01896999 NLM Identifier: NCT01896999 webcite
• [119]University of Utah: Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01998126 NLM Identifier: NCT01998126 webcite
• [120]Hoffman-LaRoche: A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT02013219 NLM Identifier: NCT02013219 webcite
• [121]Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
• [122]National Cancer Institute: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01886859 NLM Identifier: NCT01886859 webcite
• [123]Bristol-Meyers Squibb: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016). In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01472081 NLM Identifier: NCT01472081 webcite
• [124]Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
• [125]Guilhot F, Roy L, Martineua G, Guilhot J, Millot F: Immunotherapy in chronic myelogenous leukemia. Clin Lymphoma Myeloma 2007, 7(Suppl 2):S64-70.
• [126]Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS: Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014, 15:69-77.
• [127]San Antonio Military Medical Center: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–. [cited 2014 May 21] Available from: http://clinicaltrials.gov/show/NCT01570036 NLM Identifier: NCT01570036 webcite